Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 cell line AR, ER, and H3K27ac ChIP-seq]

ABSTRACT: The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 cell line AR, ER, and H3K27ac ChIP-seq]

PROVIDER: PRJNA509779 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8315180.fastq.gz	Fastqsanger.gz
	SRR8315190.fastq.gz	Fastqsanger.gz
	SRR8315181.fastq.gz	Fastqsanger.gz
	SRR8315191.fastq.gz	Fastqsanger.gz
	SRR8315182.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 19

Similar Datasets

Knockdown of EI24 in ZR-75-1 cells

Project description:Analysis of ZR-75-1 cells folowing knockdown of EI24 (P53-Induced Gene 8) and control vector. As a p53 response gene, EI24 is known to controlling cell growth, apoptosis, and autophagy. Results provide insight into the role of EI24 in epithelial-to-mesenchymal Parental ZR-75-1 cells, ZR-75-1 cells with shGFP knockdown (control), Two independent clone of knockdown of EI24 in ZR-75-1. All samples are perfomed in duplicate. Total 8 samples exist.

2013-11-20 | E-GEOD-52508 | biostudies-arrayexpress

ZR-75-1 microarray expression data

Project description:Testing the hormonal response of ZR-75-1 cells to estrogen, androgens, and a combination of both homones, with view determining the crosstalk between the transcriptional programs mediated by these hormones in breast cancer cells, and comparison with matched ChIP sequencing data for AR and ERalpha. Data analysis demonstrated reciprocal interference between 5α-dihydrotestosterone (DHT)- and estradiol (E2)-induced transcriptional programs. Specifically, regulation of 26% of E2 and 15% of DHT target genes was significantly affected by cotreatment with the other hormone, in the majority of cases (78-83%) antagonistically. Pathway analysis suggested that DHT co-treatment, for example, depleted E2-regulted pathways in cell survival and proliferation. Total RNA was extractd from luminal-like breast cancer ZR-75-1 cells in quadruplicate after treatment for 16h with 10nM of E2, DHT or E2+DHT.

2012-10-03 | E-GEOD-38132 | biostudies-arrayexpress

Knockdown of EI24 in ZR-75-1 cells

2013-11-20 | GSE52508 | GEO

Restoring miR-150-5p to an estrogen receptor positive breast cancer cell line [ZR-75-1]

Project description:The objective of these experiments is to identify novel direct and indirect targets of miR-150-5p in breast cancer cell lines. The goal is that these will give direction as to what targets or pathways may be contributing to the reduced growth observed in these cell lines upon restoration of miR-150-5p. A therapy directed towards one or more critical subtype-specific targets could be developed as a therapeutic for breast cancer patients. Using has-miR-150-5p mirVana miRNA mimic (Ambion, 4464066), miR-150-5p was restored to an estrogen receptor positive breast cancer cell line, ZR-75-1.

2017-01-01 | GSE87588 | GEO

Targets of CDK12 on ZR-75-30 breast cancer cells (RNA-seq)

Project description:RNA-sequencing analysis of CDK12 overexpressiong ZR-75-30 cell lines. Cyclin dependent kinase 12 (CDK12) is amplified in approximately 70-90% of HER2 amplified breast cancer. Results provide insight into the targets of CDK12 in HER2 positive breast cancer.

2019-07-21 | GSE117523 | GEO

ZR-75-1 microarray expression data

2012-10-03 | GSE38132 | GEO

Baseline Expression of Inflammatory Cytokines and Receptors in the ZR-75 Human Breast Cancer Cell Line

Project description:Immortalized human breast cancer cell line, ZR-75, was analyzed via RT-qPCR for transcript expression of selected cytokines and cytokine receptors associated with promotion of tumor vasculature and breast cancer metastasis

2016-05-06 | GSE80648 | GEO

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 cell line AR, ER, and H3K27ac ChIP-seq]

Project description:The role of the androgen receptor (AR) in estrogen receptor alpha (ER) positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we demonstrate that AR activation, not suppression, exerts potent anti-tumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Importantly, AR agonists combined with standard-of-care agents enhanced therapeutic responses. Mechanistically, agonist activation of AR altered the genomic distribution of ER and essential co-activators (p300, SRC-3), resulting in repression of ER-regulated cell cycle genes and up-regulation of AR target genes, including known tumor suppressors. A gene signature of AR activity positively predicted disease survival in multiple clinical ER+ breast cancer cohorts. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER+ breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.

2021-01-18 | GSE123767 | GEO

Expression analysis of breast cancer cell lines SKBR-3 and ZR-75-1 upon treatment of LMO2 overexpression or knocking-down

Project description:Investigation of whole genome gene expression level changes in ZR-75-1 cells with knocking-down of LMO2, and in SKBR-3 cells with overexpression of LMO2, compared to their relative control cells.

2017-11-18 | GSE105020 | GEO

Single-cell RNA sequencing of MCF-7, T-47D and ZR-75-1 breast cancer cell lines treated with estrogen and progesterone

Project description:In order to study transcriptional heterogeneity in response to hormone stimulation in breast cancer, we performed high-throughput single-cell RNA sequencing (scRNA-seq) on 3 breast cancer cell lines that differ in their nuclear receptor expression levels. MCF-7, T-47D and ZR-75-1 cell lines were treated with estrogen and progesterone alone or in combination and collected at different time points. Hash-tagging antibodies were used to identify samples.

2022-09-08 | GSE154873 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data